HRs (mutant/wild type) for death, according to treatment dose and gene
| Gene . | Mutant . | Wildtype . | Log-rank P . | Univariate . | Multivariable* . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median OS (months) (no. of events/total) . | 4-year OS . | Median OS (months) (no. of events/total) . | 4-year OS . | HR (95% CI) . | Wald P . | No. of events/total . | HR (95% CI) . | Wald P . | ||
| Main effect | ||||||||||
| NPM1 | 23.5 (81/130) | 40% | 16.9 (279/372) | 29% | .01 | 0.73 (0.57, 0.94) | .01 | 0.68 (0.50, 0.92) | .01 | |
| FLT3-ITD | 11.7 (118/147)) | 22% | 25.0 (303/456)) | 38% | <.0001 | 1.65 (1.33, 2.04) | <.0001 | 338/477 | 1.67 (1.28, 2.19) | .0002 |
| DNMT3A | 15.3 (95/119) | 23% | 22.8 (254/371) | 36% | .03 | 1.31 (1.03, 1.66) | .03 | 338/477338/477 | 1.54 (1.18, 2.01) | .002 |
| MLL-PTD | 16.9 (26/31) | 19% | 21.0 (405/586) | 35% | .13 | 1.36 (0.92, 2.03) | .13 | 338/477 | 0.80 (0.49, 1.30) | .36 |
| Standard dose | ||||||||||
| NPM1 | 16.9 (50/65) | 29% | 14.2 (148/180) | 24% | .30 | 0.84 (0.61, 1.16) | .30 | 186/232 | 0.93 (0.63, 1.38) | .71 |
| FLT3-ITD | 10.1 (74/83) | 17% | 20.3 (156/215)) | 34% | <.0001 | 1.77 (1.34, 2.33) | <.0001 | 186/232 | 2.10 (1.45, 3.05) | <.0001 |
| DNMT3A | 14.1 (55/61) | 13% | 16.1 (137/177) | 30% | .06 | 1.35 (0.98, 1.85) | .06 | 186/232 | 1.47 (1.03, 2.10) | .04 |
| MLL-PTD | 16.2 (16/16) | 6% | 16.5 (220/290) | 30% | .08 | 1.58 (0.95, 2.63) | .08 | 186/232 | 1.01 (0.54, 1.90) | .98 |
| High dose | ||||||||||
| NPM1 | 75.9 (31/65) | 52% | 23.3 (131/192) | 34% | .01 | 0.60 (0.41, 0.89) | .01 | 152/245 | 0.48 (0.30, 0.78) | .003 |
| FLT3-ITD | 15.2 (44/64) | 28% | 31.7 (147/241) | 42% | .04 | 1.43 (1.02, 2.01) | .04 | 152/245 | 1.35 (0.89, 2.04) | .16 |
| DNMT3A | 16.5 (40/58) | 33% | 29.2 (117/194) | 41% | .23 | 1.25 (0.87, 1.79) | .23 | 152/245 | 1.51 (0.99, 2.31) | .06 |
| MLL-PTD | 20.6 (10/15) | 33% | 27.4 (185/296) | 40% | .68 | 1.14 (0.61, 2.16) | .68 | 152/245 | 0.61 (0.27, 1.36) | .23 |
| Gene . | Mutant . | Wildtype . | Log-rank P . | Univariate . | Multivariable* . | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Median OS (months) (no. of events/total) . | 4-year OS . | Median OS (months) (no. of events/total) . | 4-year OS . | HR (95% CI) . | Wald P . | No. of events/total . | HR (95% CI) . | Wald P . | ||
| Main effect | ||||||||||
| NPM1 | 23.5 (81/130) | 40% | 16.9 (279/372) | 29% | .01 | 0.73 (0.57, 0.94) | .01 | 0.68 (0.50, 0.92) | .01 | |
| FLT3-ITD | 11.7 (118/147)) | 22% | 25.0 (303/456)) | 38% | <.0001 | 1.65 (1.33, 2.04) | <.0001 | 338/477 | 1.67 (1.28, 2.19) | .0002 |
| DNMT3A | 15.3 (95/119) | 23% | 22.8 (254/371) | 36% | .03 | 1.31 (1.03, 1.66) | .03 | 338/477338/477 | 1.54 (1.18, 2.01) | .002 |
| MLL-PTD | 16.9 (26/31) | 19% | 21.0 (405/586) | 35% | .13 | 1.36 (0.92, 2.03) | .13 | 338/477 | 0.80 (0.49, 1.30) | .36 |
| Standard dose | ||||||||||
| NPM1 | 16.9 (50/65) | 29% | 14.2 (148/180) | 24% | .30 | 0.84 (0.61, 1.16) | .30 | 186/232 | 0.93 (0.63, 1.38) | .71 |
| FLT3-ITD | 10.1 (74/83) | 17% | 20.3 (156/215)) | 34% | <.0001 | 1.77 (1.34, 2.33) | <.0001 | 186/232 | 2.10 (1.45, 3.05) | <.0001 |
| DNMT3A | 14.1 (55/61) | 13% | 16.1 (137/177) | 30% | .06 | 1.35 (0.98, 1.85) | .06 | 186/232 | 1.47 (1.03, 2.10) | .04 |
| MLL-PTD | 16.2 (16/16) | 6% | 16.5 (220/290) | 30% | .08 | 1.58 (0.95, 2.63) | .08 | 186/232 | 1.01 (0.54, 1.90) | .98 |
| High dose | ||||||||||
| NPM1 | 75.9 (31/65) | 52% | 23.3 (131/192) | 34% | .01 | 0.60 (0.41, 0.89) | .01 | 152/245 | 0.48 (0.30, 0.78) | .003 |
| FLT3-ITD | 15.2 (44/64) | 28% | 31.7 (147/241) | 42% | .04 | 1.43 (1.02, 2.01) | .04 | 152/245 | 1.35 (0.89, 2.04) | .16 |
| DNMT3A | 16.5 (40/58) | 33% | 29.2 (117/194) | 41% | .23 | 1.25 (0.87, 1.79) | .23 | 152/245 | 1.51 (0.99, 2.31) | .06 |
| MLL-PTD | 20.6 (10/15) | 33% | 27.4 (185/296) | 40% | .68 | 1.14 (0.61, 2.16) | .68 | 152/245 | 0.61 (0.27, 1.36) | .23 |
Sex, age, hemoglobin level, leukocyte count, platelet count, cytogenetics, and all 4 genes were fitted into the model.